Research ArticleArticle

Bioactivation and Covalent Binding of Hydroxyfluperlapine in Human Neutrophils: Implications for Fluperlapine-Induced Agranulocytosis

W. George Lai, Iain Gardner, Nasir Zahid and Jack P. Uetrecht
Drug Metabolism and Disposition March 2000, 28 (3) 255-263;

Abstract

The use of fluperlapine and the structurally related clozapine has been associated with the induction of agranulocytosis in humans. Unlike clozapine, fluperlapine is relatively resistant to chemical and biochemical oxidations. In this study we demonstrated that 7-hydroxyfluperlapine, the major metabolite of fluperlapine in humans, is oxidized to a reactive intermediate by HOCl and by myeloperoxidase in the presence of H2O2 and Cl−. This reactive intermediate was identified as an iminoquinone species with a M + 1 ion at m/z 324 by mass spectrometry. The iminoquinone intermediate was trapped byN-acetyl-l-cysteine (NAC) as well as GSH. NMR spectra of the NAC adducts indicated that the NAC was bound to the 6 and 9 positions of the aromatic ring. This is the same orientation as the binding of nucleophiles to the reactive metabolite of clozapine. We were able to use an antibody against clozapine to demonstrate that 7-hydroxyfluperlapine, but not fluperlapine itself, covalently modifies human myeloperoxidase. Furthermore, we demonstrated that 7-hydroxyfluperlapine is metabolized by activated neutrophils to a reactive intermediate that covalently binds to neutrophils. In the presence of NAC or GSH, such covalent binding was inhibited and the NAC or GSH adducts were formed. Thus, the reactivity and even the orientation of the binding of the reactive metabolite of 7-hydroxyfluperlapine is very similar to that of clozapine. These results provide a mechanism for the formation of a reactive metabolite of fluperlapine similar to clozapine that may explain its ability to induce agranulocytosis.

Clozapine (Fig. 1) is an atypical antipsychotic agent that has been shown to be effective in the treatment of refractory schizophrenia. Therapeutically the use of clozapine is limited because it causes agranulocytosis in approximately 0.8 to 1.0% of patients treated with the drug (Krupp and Barnes, 1989; Alvir et al., 1993). The mechanism underlying clozapine-induced agranulocytosis is at present undefined, but toxic (Veys et al., 1992; Williams et al., 1997) and immunological mechanisms (Pisciotta et al., 1992) have been proposed. We favor an innate immune mechanism (Guest et al., 1998; Uetrecht, 1999) but the formation of a reactive metabolite is likely to be the initial step in all of these proposed mechanisms.

Figure 1
Figure 1

Chemical structures of clozapine (A), fluperlapine (B), 7-hydroxyfluperlapine (C), mianserin (D), and procainamide (E).

Clozapine is oxidized to a reactive nitrenium ion by HOCl (the major oxidant of activated human neutrophils; Uetrecht, 1992b), by myeloperoxidase (MPO)1/H2O2/Cl−, and by activated human neutrophils (Liu and Uetrecht, 1995) and bone marrow cells (Maggs et al., 1995). This nitrenium ion of clozapine covalently binds to human neutrophils (Liu and Uetrecht, 1995; Gardner et al., 1998a) and bone marrow cells (Maggs et al., 1995), and it is cytotoxic to human neutrophils in vitro (Williams et al., 1997; Gardner et al., 1998b). In fact, the ability to form reactive intermediates in the presence of HOCl, MPO/H2O2/Cl−, and activated human neutrophils is one property shared by most drugs that cause a high incidence of idiosyncratic agranulocytosis (Uetrecht, 1992a).

Due to the problems associated with the clinical use of clozapine, a number of pharmaceutical companies have tried to develop antipsychotic agents that have a therapeutic profile similar to clozapine but do not cause agranulocytosis. One compound that showed early promise in this regard was the structural analog, fluperlapine (Fig. 1). Unlike clozapine, fluperlapine is relatively resistant to electrochemical and peroxidase-catalyzed oxidation (Liégeois et al., 1995). Furthermore, the carbon for nitrogen substitution at position 5 means that fluperlapine can not form a reactive nitrenium ion analogous to that seen with clozapine. Thus, from a chemical oxidation standpoint, fluperlapine would appear to be a good choice for development as a drug candidate as it would not be expected to form reactive metabolites. However, in clinical trials fluperlapine appeared to induce agranulocytosis in humans, and development of the drug was stopped, although the cases were not well documented in the literature (Müller-Oerlinghausen, 1984; Mann et al., 1987). Even though fluperlapine is resistant to chemical and peroxidase oxidation, it is extensively metabolized by the cytochromes P-450 system of both rats and humans (Dain and Jaffe, 1988; Guillouzo et al., 1988; Fischer and Wiebel, 1990; Fischer et al., 1992) (Fig.2). In humans, the major metabolite formed is 7-hydroxyfluperlapine. In this work we show that 7- hydroxyfluperlapine, unlike the parent fluperlapine, is readily oxidized by HOCl, MPO/H2O2/Cl−, or by activated human neutrophils to form a reactive iminoquinone species that leads to the formation ofN-acetyl-l-cysteine (NAC) or GSH adducts and binds to human neutrophils in vitro. Thus, bioactivation of 7-hydroxyfluperlapine may be involved in the mechanism of fluperlapine-induced agranulocytosis.

Figure 2
Figure 2

Major metabolic pathways of fluperlapine in vivo.

Experimental Procedures

Materials.

Clozapine, fluperlapine, and 7-hydroxtfluperlapine were generous gifts from Novartis Pharmaceuticals. H2O2 was purchased from ACP Chemicals (Montreal, Québec, Canada). NaOCl was purchased from Aldrich Chemical Company (Milwaukee, WI). MPO was obtained from Cortex Biochemical (San Leandrow, CA). NAC, GSH, casein, and thimerosal were purchased from Sigma Chemical Co. (St. Louis, MO). Nitrocellulose and stock acrylamide solution (40%) were purchased from Bio-Rad (Mississauga, Ontario, Canada). Enhanced chemiluminescence film was purchased from Amersham Canada (Oakville, Ontario, Canada) and the enhanced chemiluminescence detection reagents were purchased from Pierce Chemical Co. (Rockford, IL). Horseradish peroxidase-conjugated goat anti-rabbit IgG (H+L chains) was purchased from Zymed (San Francisco, CA). The concentration of NaOCl was determined spectrophotometrically (Hussarin et al., 1970). One unit of MPO activity was defined as the amount of enzyme that decomposed 1 μmol of H2O2 per min at 25°C and pH 6.

Analytical.

HPLC analyses were carried out on a Shimadzu HPLC system including a SPD-6A UV detector set at 254 nm (Shimadzu Corporation, Kyoto, Japan). The chromatography columns were supplied by Phenomenex (Torrance, CA). The column used for analytical work was 2 × 100 mm with a 2 × 30 mm guard column and packed with 5 μm Prodigy ODS(3). The column used for isolation of the NAC adducts was 10 × 150 mm with a 10 × 60 mm guard column and packed with 5 μm Ultracarb ODS 30. A mobile phase of water/acetonitrile (80:20, v/v) with 5 mM ammonium acetate was used unless otherwise stated.

Liquid chromatography interfaced with mass spectrometry (LC/MS) and tandem mass spectrometry (LC/MS/MS) were performed on a Perkin-Elmer Sciex API III triple quadrupole mass spectrometer (Perkin-Elmer Sciex, Thornhill, Ontario, Canada) with an IonSpray interface. Analyses were carried out with an ionizing voltage of 5000 V and orifice voltage of 65 V. 1H and 19F NMR spectra were recorded with a Varian Unity Plus 500 spectrometer (Varian Associates, Palo Alto, CA) using deuterium-substituted dimethyl sulfoxide (DMSO-d6) as the solvent. The ultraviolet and visible spectrophotometry was carried out on a Hewlett-Packard diode-array instrument (HP8452A; Hewlett-Packard Company, Palo Alto, CA).

Oxidation of 7-Hydroxyfluperlapine by HOCl.

7-Hydroxyfluperlapine (1 mM in 60:40 ethanol water containing 0.2% v/v acetic acid, 99 μl) was reacted with an aqueous solution of NaOCl (100 mM, 1 μl). This reaction mixture (5 μl) was immediately injected into the mass spectrometer. Methanol was used as the mobile phase, and the flow rate was 200 μl/min and decreased to 20 μl/min with a splitter.

The oxidation of 7-hydroxyfluperlapine was also monitored by the UV spectrophotometer. An ethanolic solution of 7-hydroxyfluperlapine (10 mM, 20 μl) and an aqueous solution of NaOCl (10 mM, 20 μl) were added to phosphate buffer (0.1 M, pH 6.0, 1960 μl) in a quartz cuvette with rapid stirring by a micro magnetic stirring bar. The reaction mixture was immediately scanned by the spectrophotometer at 2-s intervals for 30 s over a wavelength range of 200 to 600 nm.

Oxidation of 7-Hydroxyfluperlapine by MPO Enzyme System.

7- Hydroxyfluperlapine in ethanol (10 mM, 20 μl) was added to PBS (0.1 M, pH 7.0, 150 mM NaCl, 115 μl). MPO (5 U) and NAC in 0.5 M pH 8.5 phosphate buffer (100 mM, 40 μl) were also added. The reaction was initiated by addition of H2O2 (80 mM, 20 μl). The mixture was incubated at room temperature for 30 min, before being analyzed using HPLC and LC/MS. In the control experiments, H2O2 was replaced by water.

Preparation of NAC Adducts of the Reactive Intermediate for NMR Studies.

7-Hydroxyfluperlapine (10 mg, 0.031 mmol) was dissolved in ethanol (3.1 ml) and added to PBS (0.1 M, pH 6.5, 17.6 ml) in a 50-ml Erlenmeyer flask. MPO (50 U) and NAC (100 mg, 0.62 mmol) in phosphate buffer (0.5 M, pH 8.5, 17.6 ml) were then added. The reaction was started by the addition of H2O2 (80 mM, 3.1 ml) and stirred at room temperature for 5 h. The solvents were then removed by rota-evaporation, and the residue was redissolved in water. Solid phase extraction was subsequently carried out using water and methanol with a Supelco C-18 cartridge (Supelco Inc., Bellefonte, PA). The methanol fraction of the extraction was collected and concentrated. The products were additionally purified by HPLC with a mobile phase of water/acetonitrile (85:15, v/v) with 5 mM ammonium acetate and a flow rate of 5 ml/min. The fractions with retention times of 17 and 40 min were collected separately. HPLC analysis showed the purity of the final products was more than 95%.

Human Leukocyte Isolation.

Neutrophils and peripheral blood mononuclear cells were isolated from venous blood of healthy volunteers as described previously (Liu and Uetrecht, 1995). Trypan blue exclusion showed the initial viability to be more than 98% for all preparations. Cytospin slides were prepared and stained with Wright's stain. Light microscopy confirmed that >90% of the cells had characteristic neutrophil morphology.

Incubation of Neutrophils with Fluperlapine, 7-Hydroxyfluperlapine, and Clozapine.

Neutrophils, 5 × 106 in 1 ml of Hanks' balanced salt solution (without phenol red), were incubated with various concentrations of fluperlapine (0–50 μM), 7-hydroxyfluperlapine (0–50 μM), and clozapine (0–8 μM) at 37°C for 1 h in a shaking water bath in the presence or absence of phorbol 12-myristate-13-acetate (PMA; 40 ng/ml). PMA was dissolved in DMSO and control incubations received an equal volume of DMSO (5 μl/ml). In some experiments the ability of NAC, GSH, orN-acetyl-l-lysine (5 mM) to inhibit covalent binding of reactive metabolites to neutrophils was examined. At the end of the incubation period, cells were pelleted by centrifugation (500g, 5 min) and resuspended in cell lysis buffer (10 mM Tris-HCl, pH 7.4; 1 mM EDTA; 0.2% Triton X-100; 100 μl). A portion of the lysed sample was used for the determination of protein concentrations and the remainder of the sample was diluted with an equal volume of SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer containing dithiothreitol (6 mg/ml). The samples were then boiled at 100°C for 10 min before loading on the gel.

After the incubation of 7-hydroxyfluperlapine (50 μM) and neutrophils (5 × 106) in the presence of NAC or GSH (5 mM), the supernatants were collected and solvents were removed by a stream of nitrogen at 25°C. The samples were redissolved in water and analyzed by LC/MS using selective ion monitoring (SIM) atm/z 487 for NAC adducts and atm/z 631 for GSH adducts. LC/MS/MS spectra of the NAC and GSH adducts were also obtained under appropriate collision-activated dissociation (CAD) conditions.

Covalent Binding of Fluperlapine and 7-Hydroxyfluperlapine to Human MPO.

Fluperlapine or 7-hydroxyfluperlapine (0–50 μM; 0.1 ml) was incubated with MPO (1 or 5 U) in the presence of H2O2 (100 μM). After incubation for 30 min at 37°C, the reaction was stopped by cooling the sample on ice, and an equal volume of SDS-PAGE sample buffer containing dithiothreitol (6 mg/ml) was added. The samples were then boiled at 100°C for 10 min before analysis by SDS-PAGE.

Production of Anticlozapine-NAC-Keyhole Limpet Hemocyanin (KLH) Antiserum.

The polyclonal anticlozapine-NAC-KLH antiserum used in these studies was raised as described previously (Gardner et al., 1998a). As well as recognizing clozapine, this antiserum has been shown by immunoblot inhibition experiments to recognize structural analogs of clozapine such as olanzapine. Similar hapten inhibition experiments (see below for details) were performed with fluperlapine and hydroxyfluperlapine to ensure that the antiserum would also recognize these two structural analogs.

Hapten Inhibition Experiments.

To produce clozapine-modified neutrophils for use in the hapten inhibition experiments, the following method was used. Clozapine (20 μM in PBS pH 6.0) was reacted with NaOCl (18 μM) to generate clozapine-reactive metabolite and human neutrophils (5 × 106 in 1 ml of Hanks' balanced salt solution without phenol red) were added immediately to the reactive metabolite solution as described previously (Gardner et al., 1998a). After incubation at 37°C for 15 min the neutrophils were collected by centrifugation and lysed in cell lysis buffer. A portion of the lysed sample was used for the determination of protein concentrations, and the remainder of the sample was diluted with an equal volume of SDS-PAGE sample buffer containing dithiothreitol (6 mg/ml). The samples were then boiled at 100°C for 10 min before loading on the gel.

SDS-PAGE and Immunoblotting.

Samples for analysis by SDS-PAGE were solubilized by boiling for 10 min in sample buffer [8% (w/v) SDS, 20% (v/v) glycerol, 0.002% bromophenol blue, 125 mM Tris-HCl (pH 6.8)] containing dithiothreitol (6 mg/ml). SDS-PAGE was performed using a mini-gel system (Mini-PROTEAN II, Bio-Rad, Mississauga, Ontario, Canada) and the discontinuous buffer system described by Laemmli (1970). Stacking and resolving gels were 4 and 10% acrylamide, respectively. Gels were run at 200 V until the dye front reached the bottom of the resolving gel (∼45 min). Electrophoretic transfer of resolved proteins to nitrocellulose was carried out using a buffer of 15.7 mM Tris, 120 mM glycine (pH 8.3) containing 20% (v/v) methanol, for 60 min at 100 V using a mini Trans-Blot transfer cell (Bio-Rad). Nitrocellulose was either stained for protein for 5 min using 0.1% amido black 10B in 45% (v/v) methanol, 10% (v/v) acetic acid and then destained using 70% (v/v) methanol, 2% (v/v) acetic acid or used for antibody development. Comprehensive details of the immunoblotting methods used have been published previously (Gardner et al., 1998a).

In experiments to determine the specificity of the anticlozapine-NAC-KLH antiserum, the antiserum (1:4,000 final dilution) was incubated with various concentrations (0–20 μM) of clozapine, fluperlapine, 7-hydroxyfluperlapine, mianserin, and procainamide (see Fig. 1 for structures) for 30 min before addition of the primary antiserum to the nitrocellulose membrane. Clozapine, fluperlapine, and procainamide were dissolved in PBS; mianserin was dissolved in H2O; and 7-hydroxyfluperlapine was dissolved in ethanol. Control samples received an equivalent volume of ethanol. The washing and subsequent development of the immunoblots were then performed as outlined previously (Gardner et al., 1998a).

Other Methods.

Protein concentration was determined using a BCA protein assay kit (Pierce, Rockford, IL) with BSA as the standard.

Results

Oxidation of 7-Hydroxyfluperlapine by HOCl.

7-Hydroxyfluperlapine was easily oxidized by HOCl. On oxidation, a major reactive intermediate of 7-hydroxyfluperlapine was detected by mass spectrometry with a M + 1 ion at m/z 324. This is 2 mass units less than the M + 1 ion of the parent drug and is presumed to be the iminoquinone shown in Fig.3A. The mass spectrum of the iminoquinone species of 7-hydroxyfluperlapine obtained under CAD condition gave fragment ions at m/z 58 [85%; (CH2)2NHCH3+],m/z 84 [70%; CH2CHN(CH3)CH2CH2+],m/z 101 (100%; CH3N(CH2CH2)2NH2+),m/z 226 (50%; MH+ − methylpiperazine), m/z 252 [50%; MH+ − (CH3)2N(CH2CH2)], and m/z 267 [75%; MH+ − (CH2)2NCH3)], as well as the MH+ ion of the iminoquinone atm/z 324 (75%) (Fig. 3B).

Figure 3
Figure 3

Mass spectra of the iminoquinone intermediate produced by reacting 7-hydroxyfluperlapine with HOCl.

A, mass spectrum containing the iminoquinone (m/z 324), unreacted 7-hydroxyfluperlapine (m/z 326), and stable additionally hydroxylated product(s) (m/z 342); B, mass spectrum of the iminoquinone intermediate obtained under CAD condition.

On addition of equal equivalent of HOCl, 7-hydroxyfluperlapine there was an increase in absorptions at 308 and 420 nm, which then decreased rapidly (Fig. 4). Analyzed by LC/MS, the resultant iminoquinone species showed reactivity toward both water and chloride ion forming stable products with molecular ions ofm/z 342 and 360, respectively. The stable product with m/z 360 contained the characteristic chlorine isotope peak at m/z 362.

Figure 4
Figure 4

Repetitive absorption spectra from the reaction of 7-hydroxyfluperlapine with HOCl at pH 6.

The dashed curve is the UV spectrum of 7-hydroxyfluperlapine, and the dotted curve is the UV spectrum obtained immediately after addition of HOCl. Times for integration, cycle, and total run were 0.5, 2, and 30 s, respectively. The concentrations of 7-hydroxyfluperlapine and HOCl were 100 μM each.

Oxidation of 7-Hydoxylfluperlapine by MPO Enzyme System and Formation of 7-Hydroxyfluperlapine-NAC Adducts.

7- Hydroxyfluperlapine was extensively oxidized by human MPO in the presence of H2O2 and Cl−. When NAC was also present in the reaction mixture, the reactive iminoquinone intermediate preferentially reacted with NAC rather than water or chloride, and subsequently it could be detected as 7-hydroxyfluperlapine-NAC adducts. The LC/MS analysis of the reaction mixture showed two major peaks of the NAC adducts with the protonated molecular ions of m/z 487 and retention times of 5.0 and 6.0 min, respectively, whereas the stable water or chloride adducts were not detected (Fig.5). Each HPLC peak of NAC adduct contained a pair of diastereomers of that NAC adduct, and they were not separable by HPLC. In the control experiments, when H2O2 was replaced by water, the NAC adducts were not detected. The LC/MS/MS of the diastereomeric NAC adducts with a retention time of 5.0 min showed major CAD fragments at m/z 84 [20%; CH2CHN(CH3)CH2CH2+],m/z 301 [60%; MH+ − C5H8O3N − (CH2)2NCH3+ H], m/z 358 (100%, MH+− C5H8O3N + H), and the parent ion at m/z 487 (50%; MH+). The LC/MS/MS of the diastereomeric NAC adducts with a retention time of 6.0 min showed major CAD fragments at m/z 84 [25%; CH2CHN(CH3)CH2CH2+],m/z 301 [75%; MH+ − C5H8O3N − (CH2)2NCH3+ H], m/z 358 (100%, MH+− C5H8O3N + H) and the parent ion at m/z 487 (40%; MH+) (Fig. 6A).

Figure 5
Figure 5

LC/MS spectrum of reaction mixture when 7-hydroxyfluperlapine was oxidized by MPO/H2O2/Cl-in presence of NAC (A); and the computer extraction of ions (B) at m/z 487 (for the NAC adducts), m/z 342 (for stable hydroxylated products, not observed), and m/z 360 (for stable chlorinated products, not observed).

Figure 6
Figure 6

LC/MS/MS spectrum of the major 7-hydroxyfluperlapine-NAC adducts with a HPLC retention time of 6.0 min (A) and LC/MS/MS spectrum of the major 7-hydroxyfluperlapine-GSH adducts with a HPLC retention time of 4.2 min (B).

Each pair of the diastereomeric NAC adducts were isolated successfully using the procedure described in Experimental Procedures. The positions where NAC covalently modified hydroxyfluperlapine were demonstrated by NMR spectroscopy. In 1H NMR, the aromatic region of the diastereomeric NAC adducts with a retention time of 5.0 min showed peaks at δ 7.28 to 7.46 ppm (4H, m), and two doublet peaks at δ 6.77 and δ 6.83 ppm that had the same coupling constant of J = 9.5 Hz, and together they integrated to 1H. The aromatic region of the 1H NMR of the diastereomeric NAC adducts with a retention time of 6.0 min consisted of peaks at δ 7.28 to 7.46 ppm (4H, m), and one doublet peak at δ 6.79 ppm (1H, d, J = 12.5 Hz). By comparison, the aromatic region of the 1H NMR of 7-hydroxyfluperlapine showed peaks at δ 7.26 to 7.44 ppm (4H, m), δ 6.76 ppm (1H, d, J = 9.5 Hz), δ 6.72 ppm (1H, d, J = 12.5 Hz) (Fig.7). For 7-hydroxyfluperlapine, the doublet peak at 6.76 ppm was due to H-6, whose coupling with19F on its meta position was JHF = 9.5 Hz; the doublet peak at 6.72 ppm was due to H-9, whose coupling with the same 19F on its ortho position gave the coupling constant of JHF = 12.5 Hz. The two doublet peaks with the same coupling constants of 9.5 Hz given by the two diastereomers of NAC adduct with a retention time of 5.0 indicated that the NAC was bound to position 9 of 7-hydroxyfluperlapine. Similarly, the overlapping doublet peaks with the coupling constant of 12.5 Hz given by the two diastereomers of NAC adduct with a retention time of 6.0 min indicated that the NAC was bound to position 6 of 7-hydroxyfluperlapine. The assignment of binding positions of NAC in the NAC adducts was additionally supported by 19F NMR. The19F in 7-hydroxyfluperlapine had a doublet of doublets at δ –139.35 ppm with J′ = 12.5 Hz and J" = 9.5 Hz, which was due to the coupling with H-9 and H-6, respectively. However, the 19F in the diastereomeric NAC adducts with a retention time of 5.0 min contained two doublet peaks having the same coupling constant of JHF = 9.5 Hz at δ −130.75 ppm and δ −130.96 ppm, respectively; the 19F in the diastereomeric NAC adducts with a retention time of 6.0 min contained two doublet peaks having the same coupling constant of JHF = 12.5 Hz at δ −135.79 ppm and δ – 135.90 ppm, respectively. From 19F NMR, the loss of coupling with H-6 in the pair of diastereomers with a retention time of 5.0 min and the loss of coupling with H-9 in the diastereomers with a retention time of 6.0 min confirmed that NAC was bound to positions 6 and 9.

Figure 7
Figure 7

Proton NMR spectra of the aromatic regions of 7-hydroxyfluperlapine (A); the pair of diastereomeric NAC adducts with a HPLC retention time of 5.0 min (B); and the pair of diastereomeric NAC adducts with a HPLC retention time of 6.0 min (C).

Metabolism of 7-Hydroxyfluperlapine by Human Neutrophils in Presence of NAC or GSH.

7-Hydroxyfluperlapine was metabolized by PMA-activated human neutrophils at pH 7.4. In the presence of NAC, two pairs of 7-hydroxyfluperlapine-NAC adducts with protonated molecular ions ofm/z 487 were also detected using LC/MS in the SIM mode. Their LC/MS/MS spectra and HPLC retention times indicated that they were the same as those adducts obtained in the MPO enzyme system. The NAC adducts showed retention times at 5.0 and 6.0 min, with the approximate ratio of 1:2. The two diastereomeric adducts with NAC attached to position 6 remained dominant. When GSH was used instead of NAC, 7-hydroxyfluperlapine-GSH adducts with protonated molecular ions of m/z 631 were detected using LC/MS in the SIM mode. The GSH adducts also showed two major peaks with retention times of 3.2 and 4.0 min, respectively. It is probable that each peak consisted of a pair of diastereomers, and the dominant pair had a retention time of 4.0 min and GSH substitution at position 6. However, the ratio of the two pairs of diastereomers of GSH adducts was 1:3 in favor of the substitution on position 6. The LC/MS/MS of the adducts showed similar CAD fragments with major peaks atm/z 301 (40%; 7-hydroxyfluperlapine +S-(CH2)2NCH3+ H), m/z 358 (100%; 7-hydroxyfluperlapine + S + H), m/z 502 (20%; MH+ − C5H8O3N), and the parent ion at m/z 631 (MH+; Fig. 6B).

Recognition of Fluperlapine by Anticlozapine-NAC-KLH Antiserum.

Hapten inhibition studies demonstrated that, in immunoblot experiments, the recognition of the clozapine-reactive metabolite-modified neutrophil proteins by the antiserum could be completely inhibited by preincubation of the antiserum with clozapine, fluperlapine, and 7-hydroxyfluperlapine at concentrations of 2 (Fig.8B) or 20 μM (Fig. 8A). Mianserin, in which the piperazine is fused to the dibenzoazepine ring, inhibited the antiserum binding completely at a concentration of 20 μM but only partially at the lower concentration (Fig. 8). Procainamide, which lacks the piperazine ring but still has a tertiary amine group, was a much weaker inhibitor of antibody recognition. Using a wider range of fluperlapine concentrations, the IC50 for inhibition of the antiserum binding was determined to be approximately 10 nM (data not shown). This is similar to that reported previously for olanzapine (Gardner et al., 1998a).

Figure 8
Figure 8

Inhibition of the binding of the anticlozapine-NAC-KLH antiserum to clozapine-modified neutrophils by fluperlapine and other drugs.

The ability of clozapine (CLOZ), fluperlapine (FLU), hydroxyfluperlapine (HF), mianserin (MIAN), and procainamide to inhibit the binding of anticlozapine-NC-KLH antiserum to neutrophils incubated with NaOCl (−) or NaOCl and clozapine (+) was examined. The concentration of the inhibitors was 20 μM in A and 2 μM in B. The antiserum (1:4000 dilution) was incubated with the drugs for 30 min before addition to the nitrocellulose membrane. Protein loading was 10 μg/lane and 10% resolving gels were used. This figure is representative of two independent experiments.

Immunoblotting of Neutrophils Exposed to Fluperlapine, 7- Hydroxyfluperlapine, and Clozapine In Vitro.

When neutrophils were incubated with 7-hydroxyfluperlapine (0–50 μM) in the presence of PMA, the metabolite became covalently bound to a number of neutrophil polypeptides (Fig.9). At concentrations of 2, 5, or 10 μM, a number of 7-hydroxyfluperlapine-modified polypeptides between 45 and 116 kDa were observed. At the highest concentration of 7- hydroxyfluperlapine used (20 μM), a wide range of neutrophil polypeptides became covalently modified. However, in the absence of PMA, this binding was not observed. When clozapine (0.5 or 5 μM) was incubated with human neutrophils in the presence of PMA, the major polypeptides modified also had molecular masses of between 45 and 116 kDa but the pattern was somewhat different (Fig. 9). Covalent binding of fluperlapine to human neutrophil polypeptides was not observed in either the presence or absence of PMA (Fig. 9). The recognition of clozapine and 7-hydroxyfluperlapine-modified polypeptides by the antiserum could be inhibited by preincubating the antiserum with clozapine or hydroxyfluperlapine (Fig.10), indicating that this binding represented specific recognition of drug-modified polypeptides by the antiserum. Covalent binding of reactive metabolites of clozapine (Fig.11A) and hydroxyfluperlapine (Fig. 11B) to PMA-activated human neutrophils in vitro could be inhibited by including the nucleophiles NAC or GSH in the incubation. No such inhibition was observed whenN-acetyl-l-lysine was included in the incubation. In fact, N-acetyl-l-lysine appeared to increase the binding, which is difficult to explain.

Figure 9
Figure 9

Immunochemical detection of covalent binding of clozapine (CLOZ), 7-hydroxyfluperlapine (HFLU), and fluperlapine to PMA-stimulated human neutrophils in vitro.

Neutrophils were incubated with varying concentrations of drugs in the presence (+) or absence (−) of PMA at 37°C for 1 h and then processed as described in Experimental Procedures. Protein from 0.5 × 106 PMA-activated neutrophils (15 μg) was loaded in each lane. For immunoblotting primary antiserum (anticlozapine-NAC-KLH) was used at a dilution of 1:3000. This figure is representative of three individual experiments.

Figure 10
Figure 10

Hapten inhibition experiments.

Human neutrophils were incubated with clozapine (8 μM; C) or hydroxyfluperlapine (50 μM; H) in the presence of PMA (40 ng/ml) for 60 min at 37°C. Control incubations (−) contained PMA alone but no drug. The blots were incubated with the anticlozapine-NAC-KLH antiserum alone (dilution 1:5000) or with antiserum that was preincubated with clozapine (CLOZ; 50 μM) or fluperlapine (FLUP; 50 μM) for 30 min before addition to the blot. Protein loading was 8.7 μg/lane.

Figure 11
Figure 11

Effect of nucleophiles on covalent binding of clozapine and 7-hydroxyfluperlapine to PMA-activated human neutrophils in vitro.

Human neutrophils were incubated with clozapine (8 μM) (A) or hydroxyfluperlapine (50 μM) (B) and neutrophils were activated with PMA (40 ng/ml). The neutrophils were then incubated at 37°C for 1 h and processed as described in Experimental Procedures. The effect of including 5 mM GSH, NAC, orN-acetyl-l-lysine (NAL) in the incubations was examined. Anticlozapine-NAC-KLH antiserum was used at a dilution of 1:5000 and protein loading was 18.6 μg/lane for clozapine samples and 6.3 μg/lane for hydroxyfluperlapine samples.

Covalent Binding of Fluperlapine and 7-Hydroxyfluperlapine to Human MPO In Vitro.

When human MPO was incubated with 7-hydroxyfluperlapine (0–50 μM) in the presence of H2O2 (100 μM), the metabolite became covalently bound to the protein in a concentration-dependent manner and was detected as a 58-kDa adduct by immunoblotting (data not shown). In addition, some high molecular weight aggregates of 7-hydroxyfluperlapine-modified MPO were observed. No covalent binding was observed in the absence of drug or H2O2. No such binding was observed when parent fluperlapine was incubated under identical conditions (data not shown).

Discussion

As a potential replacement for the antipsychotic drug, fluperlapine shares many structural similarities with clozapine (Fig.1). However, replacing the secondary amine at position 5 with a methylene carbon prevents fluperlapine from forming a nitrenium ion analogous to clozapine. The results from the current study demonstrate that although fluperlapine is unreactive, its major metabolite, 7-hydroxyfluperlapine, is readily oxidized to a reactive intermediate by HOCl, which is the major oxidant produced by activated neutrophils. The mass spectrum, UV spectrum, and identity of the adducts formed on addition of nucleophiles provide substantive evidence that the reactive intermediate is the iminoquinone shown in Fig.12. Another possible structure for the reactive intermediate is a quinoneiminium ion involving the piperazine ring. Such a quinoneiminium ion would be expected to readily hydrolyze to give a quinone analog and the free piperazine. The hydrolysis of a similar intermediate of vesnarinone has been reported previously (Uetrecht et al., 1994). However, we failed to find any hydrolytic products of the proposed quinoneiminium ion or any GSH or NAC adduct of the hydrolytic product.

Figure 12
Figure 12

Proposed bioactivation pathway of fluperlapine.

The tricyclic backbone of 7-hydroxyfluperlapine is not a coplanar structure. Due to the sp3 hybridization on C-5 and the nontwisting π bond between N-10 and C-11, the seven-membered ring is bent and forces the two aromatic rings to the same side of the molecule. This configuration creates a chiral center. The two enantiomers of 7- hydroxyfluperlapine are probably not interchangeable because a completely planar and high-energy transition state would be required for such an interchange. The chirality of 7-hydroxyfluperlapine is demonstrated by its proton NMR spectrum in which the two diastereotopic protons on C-5 near the chiral center are split into a doublet of doublets (δ 3.4–3.6 ppm, J′ = 48.3 Hz, J" = 13.0 Hz).

The iminoquinone species generated from 7-hydroxyfluperlapine is electrophilic and preferentially reactive toward sulfhydryl-containing nucleophiles. In the presence of NAC or GSH, the prechiral iminoquinone intermediate generates two pairs of diastereomeric NAC or GSH adducts. The CAD mass spectra of both NAC and GSH adducts show the common major fragment at m/z 358, which is generated from the loss of the NAC or GSH moiety with sulfur still attaching to 7-hydroxyfluperlapine. This suggests that NAC and GSH are bound to the aromatic ring (Fig. 6). The proton NMR spectra of the NAC adducts show that the binding of the substituents are to positions 6 and 9 (Fig. 7). The same set of NAC and GSH adducts were also obtained with MPO/H2O2/Cl−enzyme system (Fig. 5A) and with PMA-activated human neutrophils (data not shown). Hence, we presume that the same iminoquinone intermediate is formed by activated neutrophils. The positions to which NAC and GSH bind to the reactive metabolite of 7-hydroxyfluperlapine are the same as when they bind to the reactive metabolite of clozapine and its other analogs (Liu and Uetrecht, 1995). Also analogous to the reactive metabolite of clozapine, the iminoquinone was shown to be unreactive toward the “harder” nucleophile,N-acetyl-l-lysine. Therefore, it is reasonable to speculate that the iminoquinone of 7-hydroxyfluperlapine will modify sulfhydryl-containing proteins in a manner similar to that of the nitrenium ion generated from clozapine and olanzapine. These results also provide the justification for the attempt to use the anticlozapine antibodies for the detection of 7-hydroxyfluperlapine-modified proteins.

Using the clozapine-NAC-KLH adduct as an immunogen, a polyclonal antiserum had been generated previously. This antiserum also recognized fluperlapine and its 7-hydroxyl metabolite, with high affinity. With fewer structural similarities to clozapine, mianserin and procainamide had lower affinities for the antiserum (Fig. 8). It seems that the presence and orientation of the methylpiperazine ring is important for high-affinity binding of the antibodies. Therefore, we were able to use this antiserum to investigate covalent binding of the reactive intermediate generated by 7-hydroxyfluperlapine to human neutrophil proteins.

At various concentrations (2–20 μM), 7-hydroxyfluperlapine covalently bound to PMA-activated human neutrophils. Western blotting shows that both clozapine and 7-hydroxyfluperlapine modify a neutrophil polypeptide with the molecular mass of 58 kDa, which we suspect is MPO. However, when compared with clozapine, 7- hydroxyfluperlapine tends to modify neutrophil polypeptides with higher molecular masses. When fluperlapine was incubated with PMA-activated neutrophils, no fluperlapine-modified protein was detected even when higher concentrations were used. Fluperlapine is inert toward oxidation chemically and biochemically, whereas its 7-hydroxyl metabolite is bioactivated to the reactive iminoquinone, which forms covalent adducts with sulfhydryl-containing nucleophiles. Hence, it is probable that the iminoquinone generated by activated neutrophils is also responsible for the covalent binding of 7-hydroxyfluperlapine to neutrophil proteins.

In the presence of GSH or NAC (5 mM), the neutrophil protein modification by the iminoquinone intermediate of 7-hydroxyfluperlapine was effectively inhibited (Fig. 11B). In these experiments, the 7-hydroxyfluperlapine-GSH or 7-hydroxyfluperlapine-NAC adducts were subsequently detected in the incubation supernatant by LC/MS in SIM mode. These results indicate that most of the reactive iminoquinone species formed by activated neutrophils is generated extracellularly and it is trapped by added GSH or NAC before it can bind to cellular proteins. This observation is in accord with the previous studies on neutrophil activation, which show the release of MPO enzyme by neutrophils on external stimulation (Bentwood and Henson, 1980; Chatham et al., 1994). Hence, much of the binding may occur to surface proteins; however, this does not exclude the possibility that some of the extracellularly-formed reactive species may bind to intracellular proteins.N-Acetyl-l-lysine did not inhibit the binding of neutrophil proteins by the iminoquinone and there was noN-acetyl-l-lysine adduct detected in the supernatant. This implies that the iminoquinone intermediate selectively reacts with sulfhydryl nucleophiles and only binds to sulfhydryl-containing proteins. This is similar to the reactivity of the nitrenium ion of clozapine.

The covalent binding of the iminoquinone to MPO was demonstrated using purified human MPO in presence of H2O2 and Cl−. With 7-hydroxyfluperlapine at a concentration as low as 2 μM, the MPO was modified by the bioactivated reactive intermediate. The modified MPO polypeptide has a molecular mass of 58 kDa, which is the heavy subunit of the enzyme (Andrews and Krinski, 1981). The MPO is presumably bound by the iminoquinone intermediate via its cysteine residues. A proposed bioactivation pathway for fluperlapine is summarized in Fig. 12.

It has been widely believed that the bioactivated reactive intermediates are probably responsible for most drug-induced idiosyncratic reactions. Iminoquinones are reactive Michael acceptors, and their formation from drugs has been associated with several idiosyncratic drug reactions. For example, the iminoquinone intermediates of acetaminophen and amodiaquine generated by liver cytochrome P-450 enzymes have been implicated in the idiosyncratic hepatitis caused by these drugs (Jewell et al., 1995;Parkinson, 1996; Chen et al., 1998). The same iminoquinone metabolite of amodiaquine is also formed by activated human neutrophils and may be responsible for the drug-induced agranulocytosis (Winstanley et al., 1990; Tingle et al., 1995). It has also been shown that many other drugs associated with high incidence of agranulocytosis can be oxidized to iminoquinone-type intermediates (Uetrecht, 1992a; Uetrecht et al., 1994; Ju and Uetrecht, 1999). Even though nominally the reactive metabolite of fluperlapine is different from that of clozapine, i.e., iminoquinone rather than nitrenium ion, the reactivity, orientation of binding, and physical structure of the two are very similar. We propose that the subsequent covalent binding and/or redox cycling of this reactive intermediate is responsible for fluperlapine-induced agranulocytosis and subsequent steps in the mechanism may be very similar to those involved in clozapine-induced agranulocytosis. The current study also suggests that during studies of the mechanism of an idiosyncratic drug reaction, in addition to testing the ability of the drug to form a reactive metabolite, the additional metabolism of the major stable metabolites should also be investigated.

Acknowledgments

We thank Dr. R. A. McClelland for his suggestions and comments regarding the interpretation of NMR spectra and the structures of the adducts. We also thank Novartis Pharmaceuticals for providing samples of clozapine, fluperlapine, and 7- hydroxyfluperlapine.

Footnotes

  • Send reprint requests to: Dr. Jack Uetrecht, Faculty of Pharmacy, University of Toronto, 19 Russell Street, Toronto, Ontario, Canada M5S 2S2. E-mail: jack.uetrecht{at}utoronto.ca

  • This work was supported by Medical Research Council of Canada Grant MT-13478. I.G. was supported by a postdoctoral fellowship from the Pharmaceutical Manufacturers Association of Canada and the Medical Research Council of Canada; G.L. was supported by a postgraduate studentship from the Pharmaceutical Manufacturers Association of Canada and the Medical Research Council of Canada.

  • Abbreviations used are::
    MPO
    myeloperoxidase
    CAD
    collision-activated dissociation
    DMSO
    dimethyl sulfoxide
    KLH
    keyhole limpet hemocyanin
    LC/MS
    liquid chromatography interfaced with mass spectrometry
    LC/MS/MS
    liquid chromatography interfaced with tandem mass spectrometry
    NAC
    N-acetyl-l-cysteine
    PMA
    phorbol 12-myristate-13-acetate
    PAGE
    polyacrylamide gel electrophoresis
    SIM
    selective ion monitoring
    • Received August 27, 1999.
    • Accepted November 9, 1999.

References

  1. ↵
    1. Alvir JJ,
    2. Lieberman JA,
    3. Safferman AZ,
    4. Schwimmer JL,
    5. Schaaf JA
    (1993) Clozapine-induced agranulocytosis: Incidence and risk factors in the United States. N Engl J Med 329:162–167.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Andrews PC,
    2. Krinski NI
    (1981) The reductive cleavage of myeloperoxidase in half, producing enzymically active hemi-myeloperoxidase. J Biol Chem 256:411–418.
    OpenUrl
  3. ↵
    1. Bentwood BJ,
    2. Henson PM
    (1980) The sequential release of granule constituents from human neutrophils. J Immunol 124:855–862.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Chatham WW,
    2. Turkiewicz A,
    3. Blackburn WD
    (1994) Determinants of neutrophil HOCl generation: Ligand-dependent responses and the role of surface adhesion. J Leukoc Biol 56:654–660.
    OpenUrlAbstract
  5. ↵
    1. Chen W,
    2. Koenigs LL,
    3. Thompson SJ,
    4. Peter RM,
    5. Rettie AE,
    6. Trager WF,
    7. Nelson SD
    (1998) Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6. Chem Res Toxicol 11:295–301.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Dain JG,
    2. Jaffe JM
    (1988) Effect of diet and gavage on the absorption and metabolism of fluperlapine in the rat. Drug Metab Dispos 16:238–242.
    OpenUrlAbstract
  7. ↵
    1. Fischer V,
    2. Vogels B,
    3. Maurer G,
    4. Tynes RE
    (1992) The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther 260:1355–1360.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Fischer V,
    2. Wiebel FJ
    (1990) Metabolism of fluperlapine by cytochrome P450-dependent and flavin-dependent monooxygenases in continuous cultures of rat and human cells. Biochem Pharmacol 39:1327–1333.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Gardner I,
    2. Leeder J,
    3. Chin T,
    4. Zahid N,
    5. Uetrecht JP
    (1998a) A comparison of the covalent binding of clozapine to human neutrophils in vitro and in vivo. Mol Pharmacol 53:999–1008.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Gardner I,
    2. Zahid N,
    3. MacCrimmon D,
    4. Uetrecht JP
    (1998b) A comparison of the oxidation of the atypical anti-psychotic agents clozapine and olanzapine to reactive metabolites and the toxicity of these reactive metabolites to human leukocytes. Mol Pharmacol 53:991–998.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Guest I,
    2. Sokoluk B,
    3. MacCrimmon J,
    4. Uetrecht JP
    (1998) Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis. Toxicology 131:53–65.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Guillouzo A,
    2. Begue JM,
    3. Maurer G,
    4. Koch P
    (1988) Identification of metabolic pathways of pindolol and fluperlapine in adult human hepatocyte cultures. Xenobiotica 18:131–139.
    OpenUrlPubMed
  13. ↵
    1. Hussarin A,
    2. Trudell P,
    3. Repta AJ
    (1970) Quantitative spectrophotometric method for determination of sodium hypochlorite in aqueous solutions. J Pharm Sci 59:1168–1170.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Jewell H,
    2. Maggs JL,
    3. Harrison AC,
    4. O'Neill PM,
    5. Ruscoe JE,
    6. Park BK
    (1995) Role of hepatic metabolism in the bioactivation and detoxication of amodiaquine. Xenobiotica 25:199–217.
    OpenUrlPubMed
  15. ↵
    1. Ju C,
    2. Uetrecht JP
    (1999) Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. J Pharmacol Exp Ther 288:51–56.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Krupp P,
    2. Barnes P
    (1989) Leponex-associated granulocytopenia: A review of the situation. Psychopharmacology (Berl) 99:S118–S121.
  17. ↵
    1. Laemmli UK
    (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond) 227:680–685.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Liégeois JF,
    2. Rogister F,
    3. Delarge J,
    4. Pincemail J
    (1995) Peroxidase-catalysed oxidation of different dibenzapine derivatives. Arch Pharm (Weinheim) 328:109–112.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Liu ZC,
    2. Uetrecht JP
    (1995) Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. J Pharmacol Exp Ther 275:1476–1483.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Maggs JL,
    2. Williams D,
    3. Pirmohamed M,
    4. Park BK
    (1995) The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J Pharmacol Exp Ther 275:1463–1475.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Mann K,
    2. Bartels M,
    3. Gartner HJ,
    4. Schied HW,
    5. Wagner W,
    6. Heimann H
    (1987) Differential effects of a new dibenzo-epine neuroleptic compared with haloperidol results of an open and crossover study. Pharmacopsychiatry 20:155–159.
    OpenUrlPubMed
  22. ↵
    1. Müller-Oerlinghausen B
    (1984) A short survey on untoward effects of fluperlapine. ArzneimForsch 34:131–134.
    OpenUrlPubMed
  23. ↵
    1. Klaassen CD
    1. Parkinson A
    (1996) Biotransformation of xenobiotics. in Casarett & Doull's Toxicology: The Basic Science of Poisons, ed Klaassen CD (McGraw-Hill, New York), 5th ed. pp 113–186.
  24. ↵
    1. Pisciotta AV,
    2. Konnings SA,
    3. Ciesemier LL,
    4. Cronkite CE,
    5. Lieberman JA
    (1992) Cytotoxic activity in serum of patients with clozapine-induced agranulocytosis. J Lab Clin Med 119:254–266.
    OpenUrlPubMed
  25. ↵
    1. Tingle MD,
    2. Jewell H,
    3. Maggs JL,
    4. O'Neill PM,
    5. Park BK
    (1995) The bioactivation of amodiaquine by human polymorphonuclear leukocytes in vitro: Chemical mechanisms and the effects of fluorine substitution. Biochem Pharmacol 50:1113–1119.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Uetrecht JP
    (1992a) The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab Rev 24:299–366.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Uetrecht JP
    (1992b) Metabolism of clozapine by neutrophils: Possible implications for clozapine-induced agranulocytosis. Drug Saf 7(Suppl) 51–56.
  28. ↵
    1. Uetrecht JP
    (1999) New concepts in immunology relevant to idiosyncratic drug reactions: The “danger hypothesis” and innate immune system. Chem Res Toxicol 12:387–395.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Uetrecht JP,
    2. Zahid N,
    3. Whitfield D
    (1994) Metabolism of vesnarinone by activated neutrophils: Implications for vesnarinone-induced agranulocytosis. J Pharmacol Exp Ther 270:865–872.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Veys PA,
    2. Wilkes S,
    3. Shah S,
    4. Noyelle R,
    5. Hoffbrand AV
    (1992) Clinical experience of clozapine-induced neutropenia in the UK. Laboratory investigation using liquid culture systems and immunofluorocytometry. Drug Saf 7:26–32.
  31. ↵
    1. Williams D,
    2. Pirmohamed M,
    3. Naisbett D,
    4. Maggs J,
    5. Park BK
    (1997) Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: Possible role in agranulocytosis. J Pharmacol Exp Ther 283:1375–1382.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Winstanley PA,
    2. Coleman JW,
    3. Maggs JL,
    4. Breckenridge AM,
    5. Park BK
    (1990) The toxicity of amodiaquine and its principal metabolites towards mononuclear leukocytes and granulocyte/monocyte colony forming units. Br J Clin Pharmacol 29:479–485.
    OpenUrlPubMed
View Abstract
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

Bioactivation and Covalent Binding of Hydroxyfluperlapine in Human Neutrophils: Implications for Fluperlapine-Induced Agranulocytosis

W. George Lai, Iain Gardner, Nasir Zahid and Jack P. Uetrecht
Drug Metabolism and Disposition March 1, 2000, 28 (3) 255-263;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section